New treatment options with cytotoxic agents in neuroendocrine tumours View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-08-22

AUTHORS

Pascal Hammel, Olivia Hentic, Cindy Neuzillet, Sandrine Faivre, Eric Raymond, Philippe Ruszniewski

ABSTRACT

There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy. More... »

PAGES

169-172

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7

DOI

http://dx.doi.org/10.1007/s11523-012-0228-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047764482

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22911013


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Alkylating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoid Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytotoxins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Modification Methylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Repair Enzymes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Oncology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Streptozocin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Temozolomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammel", 
        "givenName": "Pascal", 
        "id": "sg:person.01355345644.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hentic", 
        "givenName": "Olivia", 
        "id": "sg:person.0736275266.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neuzillet", 
        "givenName": "Cindy", 
        "id": "sg:person.0766573165.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766573165.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre", 
        "givenName": "Sandrine", 
        "id": "sg:person.01026352014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Oncology Unit, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raymond", 
        "givenName": "Eric", 
        "id": "sg:person.0722574726.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France", 
          "id": "http://www.grid.ac/institutes/grid.411599.1", 
          "name": [
            "Service de Gastroenterologie-Pancreatologie, H\u00f4pital Beaujon, AP-HP, Facult\u00e9 Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruszniewski", 
        "givenName": "Philippe", 
        "id": "sg:person.0640551545.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6690325", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033288252", 
          "https://doi.org/10.1038/sj.bjc.6690325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-4-29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038626778", 
          "https://doi.org/10.1186/1756-8722-4-29"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08-22", 
    "datePublishedReg": "2012-08-22", 
    "description": "There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-012-0228-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "advanced digestive neuroendocrine tumours", 
      "digestive neuroendocrine tumors", 
      "numerous treatment options", 
      "neuroendocrine tumors", 
      "treatment options", 
      "peptide receptor radionuclide therapy", 
      "liver-directed therapies", 
      "non-resectable tumors", 
      "receptor radionuclide therapy", 
      "new treatment options", 
      "efficacy of temozolomide", 
      "quality of life", 
      "longer life expectancy", 
      "neoadjuvant strategies", 
      "transferase status", 
      "systemic chemotherapy", 
      "cytotoxic chemotherapy", 
      "adverse events", 
      "somatostatin analogues", 
      "longer survival", 
      "tumor bulk", 
      "medical treatment", 
      "patients", 
      "radionuclide therapy", 
      "tumor progression", 
      "therapy", 
      "cytotoxic agents", 
      "tumors", 
      "life expectancy", 
      "chemotherapy", 
      "drugs", 
      "options", 
      "careful attention", 
      "enzyme profiles", 
      "temozolomide", 
      "symptoms", 
      "progression", 
      "thermoablation", 
      "efficacy", 
      "survival", 
      "treatment", 
      "expectancy", 
      "status", 
      "agents", 
      "response", 
      "life", 
      "events", 
      "profile", 
      "analogues", 
      "addition", 
      "quality", 
      "strategies", 
      "consideration", 
      "future", 
      "attention", 
      "order", 
      "thanks", 
      "bulk", 
      "O6 methylguanine DNA methyl transferase status", 
      "methylguanine DNA methyl transferase status", 
      "DNA methyl transferase status", 
      "methyl transferase status", 
      "favourable enzyme profile", 
      "successive drugs"
    ], 
    "name": "New treatment options with cytotoxic agents in neuroendocrine tumours", 
    "pagination": "169-172", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047764482"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-012-0228-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22911013"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-012-0228-7", 
      "https://app.dimensions.ai/details/publication/pub.1047764482"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_585.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-012-0228-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-012-0228-7'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      22 PREDICATES      108 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-012-0228-7 schema:about N29be61ea8a7a47b5aaf8c2be0a93bc54
2 N2bcf54b00bb443ad84c7a5d510a19392
3 N2f2bfbd215b14486901806f2aecd1d24
4 N305f60ac60e74ba6a79095f9cd082ab8
5 N5af49ac406644e41b29635f1e0141a92
6 N62661560b3154147bbdea2d046a37615
7 N6d1d252b221a414cb90a75babed50410
8 N78c67c128c434248ba148b64a5e18ca1
9 N81654d2f41a24ea0b454a78778ca09bd
10 N8f3cb7f3c9994beb838deda5d7bda13d
11 N94cf349ce28c48dc8efdb0de328ef09c
12 Na04af40a70a845dabb2000873c69dc81
13 Na91833e5b80a4264bcb78340475e6069
14 Nae0b5bfca92b4701b9d53c36091779e7
15 Nc909fd476b834cc6925e721f4a5944d7
16 Nfe5b1f8fbbc3458dbfb170791bd24742
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Na78f0793a2284c9991ca05cfc5ad2412
20 schema:citation sg:pub.10.1038/sj.bjc.6690325
21 sg:pub.10.1186/1756-8722-4-29
22 schema:datePublished 2012-08-22
23 schema:datePublishedReg 2012-08-22
24 schema:description There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O6 methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N6156fe828ede4592933095c123df22fd
29 Nd7b0a4f8735c4f6dbdf1c423d82a8d08
30 sg:journal.1036678
31 schema:keywords DNA methyl transferase status
32 O6 methylguanine DNA methyl transferase status
33 addition
34 advanced digestive neuroendocrine tumours
35 adverse events
36 agents
37 analogues
38 attention
39 bulk
40 careful attention
41 chemotherapy
42 consideration
43 cytotoxic agents
44 cytotoxic chemotherapy
45 digestive neuroendocrine tumors
46 drugs
47 efficacy
48 efficacy of temozolomide
49 enzyme profiles
50 events
51 expectancy
52 favourable enzyme profile
53 future
54 life
55 life expectancy
56 liver-directed therapies
57 longer life expectancy
58 longer survival
59 medical treatment
60 methyl transferase status
61 methylguanine DNA methyl transferase status
62 neoadjuvant strategies
63 neuroendocrine tumors
64 new treatment options
65 non-resectable tumors
66 numerous treatment options
67 options
68 order
69 patients
70 peptide receptor radionuclide therapy
71 profile
72 progression
73 quality
74 quality of life
75 radionuclide therapy
76 receptor radionuclide therapy
77 response
78 somatostatin analogues
79 status
80 strategies
81 successive drugs
82 survival
83 symptoms
84 systemic chemotherapy
85 temozolomide
86 thanks
87 therapy
88 thermoablation
89 transferase status
90 treatment
91 treatment options
92 tumor bulk
93 tumor progression
94 tumors
95 schema:name New treatment options with cytotoxic agents in neuroendocrine tumours
96 schema:pagination 169-172
97 schema:productId N36aced05693f4c3a8a1280bd3e39ec9c
98 Nb44bfba538a64379b9c70fb2783a6ee2
99 Ne84a2b260ca44004a044d8d773bab87e
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047764482
101 https://doi.org/10.1007/s11523-012-0228-7
102 schema:sdDatePublished 2022-01-01T18:28
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher Nd6ec571bdf8f4d40a3021f866fd9c32f
105 schema:url https://doi.org/10.1007/s11523-012-0228-7
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N29be61ea8a7a47b5aaf8c2be0a93bc54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Cytotoxins
111 rdf:type schema:DefinedTerm
112 N2bcf54b00bb443ad84c7a5d510a19392 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Temozolomide
114 rdf:type schema:DefinedTerm
115 N2f2bfbd215b14486901806f2aecd1d24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name DNA Modification Methylases
117 rdf:type schema:DefinedTerm
118 N305f60ac60e74ba6a79095f9cd082ab8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Dacarbazine
120 rdf:type schema:DefinedTerm
121 N36aced05693f4c3a8a1280bd3e39ec9c schema:name doi
122 schema:value 10.1007/s11523-012-0228-7
123 rdf:type schema:PropertyValue
124 N5056ec6c8b654ef78d10f7546495c563 rdf:first sg:person.0736275266.26
125 rdf:rest N80e27edfd96343e9b6dc11b7a9f5fa41
126 N5af49ac406644e41b29635f1e0141a92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name DNA Repair Enzymes
128 rdf:type schema:DefinedTerm
129 N6156fe828ede4592933095c123df22fd schema:volumeNumber 7
130 rdf:type schema:PublicationVolume
131 N62661560b3154147bbdea2d046a37615 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antibiotics, Antineoplastic
133 rdf:type schema:DefinedTerm
134 N6d1d252b221a414cb90a75babed50410 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Neuroendocrine Tumors
136 rdf:type schema:DefinedTerm
137 N78c67c128c434248ba148b64a5e18ca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Treatment Outcome
139 rdf:type schema:DefinedTerm
140 N80e27edfd96343e9b6dc11b7a9f5fa41 rdf:first sg:person.0766573165.15
141 rdf:rest Nf5ec447912734869b56f92437debb84f
142 N81654d2f41a24ea0b454a78778ca09bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Clinical Trials as Topic
144 rdf:type schema:DefinedTerm
145 N8c9634ede9564f71bbe85dc2428deee1 rdf:first sg:person.0640551545.21
146 rdf:rest rdf:nil
147 N8f3cb7f3c9994beb838deda5d7bda13d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Quality of Life
149 rdf:type schema:DefinedTerm
150 N94cf349ce28c48dc8efdb0de328ef09c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Medical Oncology
152 rdf:type schema:DefinedTerm
153 Na04af40a70a845dabb2000873c69dc81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Streptozocin
155 rdf:type schema:DefinedTerm
156 Na78f0793a2284c9991ca05cfc5ad2412 rdf:first sg:person.01355345644.55
157 rdf:rest N5056ec6c8b654ef78d10f7546495c563
158 Na91833e5b80a4264bcb78340475e6069 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 Nae0b5bfca92b4701b9d53c36091779e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Carcinoid Tumor
163 rdf:type schema:DefinedTerm
164 Nb44bfba538a64379b9c70fb2783a6ee2 schema:name pubmed_id
165 schema:value 22911013
166 rdf:type schema:PropertyValue
167 Nc909fd476b834cc6925e721f4a5944d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Agents, Alkylating
169 rdf:type schema:DefinedTerm
170 Nd6ec571bdf8f4d40a3021f866fd9c32f schema:name Springer Nature - SN SciGraph project
171 rdf:type schema:Organization
172 Nd7b0a4f8735c4f6dbdf1c423d82a8d08 schema:issueNumber 3
173 rdf:type schema:PublicationIssue
174 Ne84a2b260ca44004a044d8d773bab87e schema:name dimensions_id
175 schema:value pub.1047764482
176 rdf:type schema:PropertyValue
177 Ne8827e42c926400ab654bca6e5200bc9 rdf:first sg:person.0722574726.55
178 rdf:rest N8c9634ede9564f71bbe85dc2428deee1
179 Nf5ec447912734869b56f92437debb84f rdf:first sg:person.01026352014.76
180 rdf:rest Ne8827e42c926400ab654bca6e5200bc9
181 Nfe5b1f8fbbc3458dbfb170791bd24742 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Tumor Suppressor Proteins
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1036678 schema:issn 1776-2596
191 1776-260X
192 schema:name Targeted Oncology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01026352014.76 schema:affiliation grid-institutes:grid.411599.1
196 schema:familyName Faivre
197 schema:givenName Sandrine
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76
199 rdf:type schema:Person
200 sg:person.01355345644.55 schema:affiliation grid-institutes:grid.411599.1
201 schema:familyName Hammel
202 schema:givenName Pascal
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355345644.55
204 rdf:type schema:Person
205 sg:person.0640551545.21 schema:affiliation grid-institutes:grid.411599.1
206 schema:familyName Ruszniewski
207 schema:givenName Philippe
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640551545.21
209 rdf:type schema:Person
210 sg:person.0722574726.55 schema:affiliation grid-institutes:grid.411599.1
211 schema:familyName Raymond
212 schema:givenName Eric
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722574726.55
214 rdf:type schema:Person
215 sg:person.0736275266.26 schema:affiliation grid-institutes:grid.411599.1
216 schema:familyName Hentic
217 schema:givenName Olivia
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736275266.26
219 rdf:type schema:Person
220 sg:person.0766573165.15 schema:affiliation grid-institutes:grid.411599.1
221 schema:familyName Neuzillet
222 schema:givenName Cindy
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766573165.15
224 rdf:type schema:Person
225 sg:pub.10.1038/sj.bjc.6690325 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033288252
226 https://doi.org/10.1038/sj.bjc.6690325
227 rdf:type schema:CreativeWork
228 sg:pub.10.1186/1756-8722-4-29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038626778
229 https://doi.org/10.1186/1756-8722-4-29
230 rdf:type schema:CreativeWork
231 grid-institutes:grid.411599.1 schema:alternateName Oncology Unit, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
232 Service de Gastroenterologie-Pancreatologie, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
233 schema:name Oncology Unit, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
234 Service de Gastroenterologie-Pancreatologie, Hôpital Beaujon, AP-HP, Faculté Denis Diderot (Paris VII), 100 boulevard Leclerc, 92110, Clichy, France
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...